NG/DOX

Stages

1. 1.
   Drug loading into nanogel(library_build)

   This stage creates the doxorubicin-loaded nanogel formulation used for downstream characterization and testing.

   Selection: Load doxorubicin into the dual-responsive nanogel to generate the NG/DOX formulation.

2. 2.
   Physicochemical and in vitro characterization(functional_characterization)

   This stage checks whether the loaded nanogel has the intended physical properties and intracellular delivery behavior before animal evaluation.

   Selection: Assess morphology, size, dual-triggered release, cell uptake, and cell proliferation inhibition in vitro.

3. 3.
   In vivo efficacy and safety validation(in_vivo_validation)

   This stage tests whether the formulation improves therapeutic performance and safety in the hepatoma mouse model.

   Selection: Evaluate antitumor efficacy versus free DOX·HCl and assess safety by body weight, histopathology, micronucleus rate, and white blood cell count.

Steps

1. 1.
   Load doxorubicin into the nanogel by sequential dispersion and dialysisdelivery harness and loaded formulation

   Generate the doxorubicin-loaded nanogel formulation NG/DOX.

   Drug loading is required before morphology, release, cellular, and in vivo testing of the formulation.

2. 2.
   Characterize morphology, size, and dual-triggered release of NG/DOXloaded formulation under characterization

   Establish that the loaded nanogel has the intended nanoscale morphology and pH/reduction-responsive release behavior.

   These characterization results provide evidence that the formulation behaves as designed before biological efficacy testing.

3. 3.
   Test cell uptake and cell proliferation inhibition in vitroloaded formulation under biological testing

   Assess whether NG/DOX is taken up by cells and inhibits cell proliferation in vitro.

   In vitro cellular testing provides biological support for proceeding to animal efficacy and safety studies.

4. 4.
   Evaluate antitumor efficacy in H22 hepatoma-bearing BALB/c mice against free DOX·HCltherapeutic formulation under in vivo comparison

   Determine whether NG/DOX improves antitumor efficacy relative to free doxorubicin hydrochloride.

   Animal testing follows in vitro support to assess therapeutic benefit in a hepatoma model.

5. 5.
   Confirm tumor suppression and assess in vivo safety by histopathology, immunohistochemistry, body weight, micronucleus rate, and white blood cell counttherapeutic formulation under confirmatory analysis

   Confirm tumor suppression activity and evaluate safety liabilities in vivo.

   These analyses provide confirmatory efficacy evidence and safety assessment after therapeutic testing in animals.